Drug Profile
Research programme: cancer and pain therapeutics - leon nanodrugs
Alternative Names: In 006; In 011; In 012Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator leon-nanodrugs
- Class Analgesics; Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Pain
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in Germany
- 28 Feb 2021 No recent reports of development identified for preclinical development in Pain in Germany
- 12 Jan 2017 Research programme: Cancer and pain therapeutics - Leon nanodrugs is available for licensing as of 12 Jan 2017. http://leon-nanodrugs.com/services/pipeline/